{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Two Interactive ePatient Cases: Early and Later-Onset Spinal Muscular Atrophy (SMA)

Activity Steps

1 Take Pre-test
2 Activity
3 Take Post-test 4Certificate

Description

To access this FREE activity, please login (or register first in a new tab). After login, click on the blue +Cart button and enter the Coupon Code: SMAFREECASES

Do you know enough about the recommended diagnostic process and best treatment practices for spinal muscular atrophy (SMA)? This 1-hour learning activity, featuring two interactive patient cases, was developed with two leading experts in the field of SMA, Dr. John Brandsema and Dr. Diana Castro; it will provide practical guidance on how to relate the optional process for early diagnosis and multidisciplinary care to your own clinical practice.

Target Audience

This activity has been designed to meet the educational needs of neurologists, pediatric neurologists, neuromuscular disease specialists, orthopedists, pulmonologists, physical therapists, and nurses involved in the management of patients with SMA.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe early signs of SMA and follow the recommended diagnostic procedure
  2. Anticipate the identification of patients through newborn screening
  3. Make a case for early treatment initiation
  4. Develop individualized care plans for treatment and multidisciplinary management of early and later-onset SMA
  5. Select and apply standardized assessment tools to monitor clinical changes in SMA
  6. Implement early interventions to reduce complications of SMA
  7. Recognize the evidence of benefit of current treatments for early and later-onset SMA

Disclosures

Dr Brandsema has disclosed that he was/is on the speaker bureau for Biogen; was/is a consultant/advisor for AveXis, Inc., Biogen, and WAVE Pharma; was/is a grant/research support recipient for Alexion Pharmaceuticals, Inc., AveXis, Inc., Biogen, Cytokinetics, Inc., CSL Behring, FibroGen, PTC Therapeutics, Sarepta Therapeutics, Inc., Summit Pharmaceuticals International, and WAVE Pharmaceuticals.

Dr. Castro disclosed that she was/is a consultant/advisor for AveXis, Inc., Biogen, PTC Therapeutics, Sarepta Therapeutics; was/is a grant/research support recipient for AveXis, Inc., Biogen, PTC Therapeutics, Sarepta Therapeutics, SRK Pharmaceuticals, Neurogene Inc., and FibroGen.

Non-Faculty All planners in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interest in, any commercial organizations pertaining to this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Lippincott CME Institute and Ology Medical Education do not recommend the use of any agent outside of the labeled indications.

Financial Support

This activity has been supported by an independent educational grant from Biogen MA, Inc.

Method of Participation

1. Site registration is required to begin this activity. Please click the blue "+Planner" button and follow the instructions to register.

2. Read the educational objectives, accreditation information, and faculty disclosures.

3. Take the pre-activity test.

4. View the two interactive ePatient cases.

5. Take the post-activity test and complete the evaluation.

6. Download certificate of CME credit.

Price: $100.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planner
Professions: Physician
Test Code: SMAWEB1219
Published: DECEMBER 2019
Expires: 1/1/2026
Sources: Grant Supported
Required Passing Score: 4/5 (80%)
Authors: John Brandsema, MD. Neuromuscular Section Head, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Diana Castro, MD. Co-Director, Muscular Dystrophy Association Clinic, UT Southwestern Medical Center, Dallas, TX, USA

Specialties: Neurology, Physical Therapy, Pulmonology
Topics: Neuromuscular Disorders , Spinal Muscular Atrophy